

Press Release

SuppreMol Raises € 9.5 million in Extended Series D Financing Round

Munich, Germany, May 21st, 2013: SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapies for the treatment of autoimmune diseases, today announced the second closing of a series D financing round receiving € 9.5 million.

The second closing of this series D round was again led by MIG AG (Munich, Germany) and Santo Holding GmbH (Holzkirchen, Germany) with BioMedPartners AG (Basel, Switzerland) as co-lead investors; Max Planck Society and FCP Biotech Holding GmbH invested also in this round. Together with the first closing from September 2012 of € 6.5 million, the total of this series D round is now € 16 million.

SuppreMol will use the funds to further advance the Phase II studies of its lead candidate SM101, a recombinant human soluble Fc-gamma receptor IIB (FcγRIIB) for the treatment of Primary Immune Thrombocytopenia (ITP) and of Systemic Lupus Erythematosus (SLE). ITP is a serious bleeding condition characterized by deficient blood clotting due to auto-antibodies destroying the body's platelets. SM101 has been granted orphan drug designation for the treatment of ITP in the EU and US and started Phase IIa clinical studies late last year. SLE is a chronic inflammatory autoimmune disease of unknown etiology affecting multiple organs, which can lead to organ failure.

"I am impressed by the strong commitment of our investors", said Dr. Klaus Schollmeier, who joined SuppreMol as CEO at the beginning of April 2013. "The financing round will enable us to advance our lead product SM101 in Phase II trials and further deepen our knowledge regarding the FcγRIIB-platform."

"This financing round signals strong confidence from our investors in SuppreMol and its lead product SM101," said Dr. Thomas Hecht, Chairman of the Advisory Board. "The additional funding will enable the company to push clinical trials towards the next value enhancing milestones."

About SuppreMol

SuppreMol GmbH is a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune and allergic diseases. The company is pioneering the development of soluble Fc-gamma receptors (FcγRs), which are recombinant autologous therapeutic proteins with a specific immunoregulatory potential. The company's lead product SM101, a recombinant soluble FcγRIIB is in Phase II clinical development for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) and has potential to treat Rheumatoid Arthritis (RA) and other autoimmune conditions. SuppreMol's pipeline also includes two antibody development programs utilizing the inhibitory effect of FcγRIIB suitable for alternative treatment strategies and indications. SuppreMol was founded as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize Laureate in Chemistry 1988, at the Max Planck Institute for Biochemistry in Martinsried, Germany. To date SuppreMol has raised about € 51 million through private investors. Major shareholders in the company include MIG Fonds, BioMedPartners AG, Santo Holding GmbH and FCP Biotech Holding GmbH along with KfW Mittelstandsbank, Bayern Kapital GmbH, Max Planck Society, and Z-Cube.

Contact

SuppreMol GmbH

Dr. Klaus Schollmeier

Chief Executive Officer

Tel: +49 89 30 90 50 680

E-mail: info@suppremol.com

www.suppremol.com